After decades of research, the mechanism by which estrogens stimulate the proliferation of epithelial cells in the endometrium and mammary gland, and in the carcinomas that arise in those tissues, is still not understood. Cells do not proliferate in response to 17␤-estradiol (E2) alone, and although it is widely recognized that growth factors play a role in E2's proliferative effect, exactly how they are involved is unclear. It has long been known that the proliferation of endometrial epithelial cells is preceded by dramatic increases in blood flow and microvascular permeability, filling the subepithelial stroma with plasma and the proteins it contains, such as IGF-I, which is known to synergize with E2 in the induction of cell proliferation. The hyperpermeability is caused by vascular endothelial growth factor (VEGF), which is rapidly induced by E2, via the transcription factors hypoxia-inducible factor 1 and estrogen receptor ␣, in luminal epithelial cells in vivo. As we recently showed, VEGF is also strongly induced in endometrial cancer cells in vitro when excessive degradation of hypoxia-inducible factor 1␣, caused by the abnormally high oxygen level to which cultured cells are exposed, is prevented. Putting these facts together, we now propose a new model of E2-induced proliferation in which VEGF-induced vascular hyperpermeability plays an essential role. E2 first induces the expression by endometrial epithelial cells of VEGF, which then acts in a paracrine manner to induce interendothelial cell gaps in subepithelial blood vessels, through which plasma and the proteins therein enter the adjacent stroma. Plasma carries even more E2, which circulates bound to proteins, and IGF-l, which together drive epithelial cells completely through the cell cycle. (Endocrinology 152: 4481-4488, 2011) 
L
ippman et al., 1976: "The mechanism by which estrogen stimulates the proliferation of certain target tissues … is incompletely understood" (1) . Gustafsson, 2003 : "One of the great enigmas of E2 action is the mechanism through which it induces cell proliferation" (2) .
Despite huge advances in our understanding of the mechanisms involved in estrogens' actions in cells over the 27-yr period bracketed by the two reviews cited above, how estrogens stimulate cell proliferation remained poorly understood and controversial. That is still the situation today, as indicated by continuing efforts to unravel this mystery (3) (4) (5) (6) (7) (8) (9) (10) . It is clear that 17␤-estradiol (E2) is the initiator of epithelial cell proliferation in the uterus (5, (11) (12) (13) (14) , and recent work has revealed that E2 is also the key factor driving epithelial cell proliferation in the mammary gland (3, 4) . Thus, E2's proliferative effect is critical for reproduction and nourishment of offspring. On the other hand, excessive exposure to E2 or other estrogenic compounds is the major risk factor for the development of carcinomas (malignancies that arise from epithelial cells) of the endometrium and breast (15) (16) (17) . Presumably, this relates in no small degree to E2's ability to induce epithelial cell proliferation (18). Understanding precisely how E2 does this, therefore, is essential for understanding normal reproduction as well as the etiology of the large majority of cancers in women.
Although research has focused on the mechanisms involved in E2 regulation of gene expression at the molecular level, almost all of which were done using cultured cancer cells, the larger physiological effects of E2 on both normal target tissues and tumors have been almost completely ignored. Recent results from our laboratory suggest that a major missing link in the understanding of E2-induced proliferation is blood vessel function (19 -24) . This omission is puzzling, because it has long been known that both the rate of endometrial blood flow and the permeability of endometrial microvessels are rapidly increased by E2 (20, (25) (26) (27) (28) . The massive exudation of plasma that results dramatically changes the endometrial microenvironment (29, 30), well before epithelial cell proliferation occurs. As we have shown (19 -23), this effect of E2 is dependent on vascular endothelial growth factor (VEGF), a powerful inducer of vascular permeability.
Several things probably explain why vascular function was left out of previous models of E2 action. First, when cells are in a plastic dish, there is no vasculature. What seems to have been completely overlooked, however, is that culture conditions, if proliferation is desired, replicate the effects of a hyperpermeable vasculature. Specifically, the cells are bathed in a growth factor-rich fluid: a complete culture medium supplemented with serum (plasma minus clotting factors). Secondly, although E2 was shown in 1993 to rapidly and strongly induce the expression of VEGF (19) in the uterus, VEGF's acute vascular effects have received no consideration in the mediation of E2-induced epithelial cell proliferation. Again, this probably results from a reliance on cultured cancer cells. As we recently showed (24), in contrast to the uterus in vivo, VEGF is not induced by E2 in endometrial cancer cells in vitro, because they lack a critical transcription factor, hypoxia-inducible factor (HIF)1␣, required for that induction (21-23). Thus, for those working on E2-induced proliferation of cancer cells, VEGF was just not relevant. Thirdly, VEGF is by far best known for its angiogenic activity (the induction of new blood vessel growth). The tremendous interest in that process and its inhibition (31) has completely overshadowed VEGF's primary biological effect, the rapid induction of increased microvascular permeability. This may have begun to change, however, because of the dramatic successes achieved using antibodies to VEGF for the treatment of age-related wet macular degeneration, a disease attributed primarily to fluid accumulation in the retina (32).
Given the importance of E2-induced cell proliferation, shortcomings of existing models (see below), and recent advances that shed new light on E2's actions, a fresh look at the subject is warranted. We will propose that VEGFinduced vascular hyperpermeability is not just conducive to but essential for E2's mitogenic effect. Through VEGF, E2 controls the exposure of cells to plasma proteins, in particular IGF-I, which an abundance of evidence has shown is an essential mediator of E2-induced epithelial and carcinoma cell proliferation (33-42).
Previous Models of E2-induced Cell Proliferation
Before discussing a new model of E2-induced cell proliferation, it is useful to review previously proposed ones (43, 44) . Two important things about these must be remembered. First, they were based largely on cell culture studies, which led to multiple models. The fact that none of these satisfactorily explained E2's proliferative effect should have been a clear indication that culture systems inadequately reflect normal in vivo conditions and events. This conclusion is strongly supported by a recent microarray study of the effects of E2 on gene expression in breast cancer cells in culture vs. the same cells grown as tumors in mice (45) . Remarkably, the overlap in the genes regulated by E2 in the two systems was only 11%. Secondly, these models were initially developed before the discovery of VEGF in 1989 (46, 47) and the demonstration of its regulation by E2 in the rat uterus in 1993 (19).
The direct positive model
The simplest model for how E2 might act was as a direct mitogen for estrogen receptor (ER)␣-expressing cells. If that were true, E2 should stimulate the proliferation of cells in a defined medium in vitro. It has been demonstrated over and over again during the last four decades, however, that E2 alone is incapable of driving cells completely through mitosis and cell division. This includes normal endometrial and mammary epithelial cells (48 -53) and ER␣-positive carcinoma cells (43, 44) . Only when peptide growth factors, usually supplied in the form of serum, are also present can any additional stimulatory effect of E2 be reliably shown. Even then, the results from different studies are highly variable and the E2 effect small compared with that of charcoal-stripped serum or growth factors alone. Often, an E2 effect can only be shown under highly manipulated conditions. Nevertheless, the direct mitogenic model is in part correct. Studies done since the late 1990s have shown that E2 does directly control the production or activity of components of the cell cycle machinery, including cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors (54 -58) . This is not sufficient to cause actual proliferation, but it promotes that process. Thus, it is perhaps useful to think of E2 in part as a "competence factor," a now rarely used term for substances that prime cells to divide in response to a second signal, such as IGF-I.
The indirect positive (estromedin) model
Because E2 is not directly mitogenic, it was then proposed that growth factors ("estromedins") mediate E2-induced cell proliferation (43, 44, 59 ). The involvement of growth factors in E2 action is now widely accepted, but numerous questions about the exact nature of the relationship remain. For example, where and when in the sequence of events between E2 exposure and cell division do growth factors act? Which factors are involved? Finally, from where do they originate and how does E2 increase their availability to epithelial cells?
With regard to the factor involved, IGF-I seems by far the most likely candidate. Numerous studies have shown that IGF-I is an essential mediator of E2-induced epithelial cell proliferation (35, 39, 42) and that E2 and IGF-I synergistically stimulate epithelial and carcinoma cell proliferation (33, 34, 36 -38, 40, 41). Furthermore, Zhu and Pollard (5) recently showed using an in vivo approach that E2's mitogenic effect on endometrial epithelial cells in mice is entirely dependent on IGF-I. With regard to where that IGF-I originates, they speculated that it was most likely produced locally, because E2 has been shown to induce IGF-I expression in the uterus (60) . There seems to be little or no direct evidence, however, that locally induced factors play the critical role in E2's effect on cell proliferation. Various mouse knockout (KO) models have been developed to differentiate the functions of local vs. liver-produced IGF-I, and although initially these supported a primary role for local IGF-I in tissue growth, the most recent ones indicate that circulating IGF-I plays a more important role than previously thought (61, 62) . This is consistent with a study by Cooke and co-workers (63) , who showed that uteri isolated from IGF-I-null neonatal mice grew to normal size after transplantation into wild-type hosts, indicating that systemic rather than locally produced IGF-I mediated E 2 -induced uterine growth. Commenting on this finding, Zhu and Pollard (5) stated that it was unclear how E2 "would make circulating IGF1 available within a short time span." As will be discussed, that action is likely the induction of VEGF, which in 1-2 h induces interendothelial cell gaps, the route required for the transit of circulating IGF-I, via plasma outflow, from the vascular to interstitial compartments (64, 65) .
A refinement of the indirect model came from a series of intriguing in vivo studies by Cunha et al. (66) . These used epithelial and stromal cells isolated from wild-type and ER␣-deficient (ERKO) mice to produce recombined endometrial and mammary tissue deficient in ER␣ selectively in one or the other compartment. The results indicated that E2 induces epithelial cell proliferation via ER␣ in stromal cells, not in the epithelial cells themselves. Questions have recently arisen, however, about this conclusion. Two studies in the mammary gland, for example, found that E 2 -induced proliferation is in fact triggered via ER␣ in the epithelial cells themselves (3, 4) . In both cases, this was attributed to the use of a complete ER␣ KO mouse; the original ERKO mouse retains significant ER␣ function (67, 68) . These studies also differed, however, from the earlier ones in one other important way: they used intact rather than ovariectomized hosts. We have recently found that luminal epithelial cells of ovariectomized mice lack ER␣ (Molitoris K.H., A.A. Kazi, and R.D. Koos, manuscript submitted). In fact, this had been reported by others but without any comment as to its functional significance (70 -72) . It is not surprising, therefore, that epithelial cells in an ovariectomized host appear not to mediate their own proliferation, because like epithelial cells from ERKO mice, they lack ER␣. We also found that this loss of ER␣ prevents E2-induced VEGF expression by epithelial cells, although that response shifts to stromal cells. This is consistent with earlier studies that localized E2-induced VEGF expression to epithelial cells in intact rodents (73) (74) (75) (76) and stromal cells in ovariectomized ones (77, 78) . It is also consistent with a role for VEGF in E2 action, because stromal cells, which become the source of E2-induced VEGF expression after ovariectomy, also then become the site through which E2 induces epithelial cell proliferation (66) .
The indirect negative model
Failure of the direct and indirect models of E2 action to satisfactorily explain E2's proliferative effect, especially persistent reports that factors from the circulation, other than E2, were involved, led to the proposal by Soto and Sonnenschein (43) that E2 acts by blocking the effects of a putative inhibitor of mitosis. This double-negative model was premised, however, on a fundamental misunderstanding of physiology: "in the animal, cells in the G 0 phase of the cycle are bathed by plasma proteins" yet "remain quiescent and healthy" (43) . In other words, these authors believed that cells are constantly exposed to plasma growth factors but do not grow, and therefore, they must be held in check by an inhibitory factor. By blocking the activity of that factor, E2 would allow its target cells to respond to plasma growth factors. In fact, cells in the body are mostly quiescent, precisely because they are effectively walled off from the plasma by the endothelial cells lining the microvasculature. The authors of this model did not consider that exposure to plasma proteins might instead be an E2-regulated event. The discovery of VEGF and the demonstration of its induction by E2 provide a tissue-specific mechanism through which that can occur.
E2 Induction of VEGF and the Consequences of Hyperpermeability
VEGF is expressed in the endometrium in an E 2 -dependent, ER␣-mediated manner (19, 77, 79) . In intact ani-mals, this occurs in the luminal epithelial cells (23, [73] [74] [75] [76] ; as noted earlier, E2-induced VEGF expression is not blocked by protein synthesis inhibitors and, thus, is an "immediate early gene" response (19, 77) . This in itself indicates that VEGF likely plays a vital role in E2's subsequent effects on the endometrium. As we have shown, the induction of VEGF by E2 requires binding of both ER␣ and HIF-1 to the VEGF promoter (21-24). The activation of HIF-1␣ by E2 is mediated by the phosphatidylinositol 3 kinase/Akt pathway (22, 23), hyperactivity of which was already known to cause endometrial cancer (80) .
In contrast to E2's effects in the uterus, cultured ER␣-positive cancer cells show only weak or no VEGF expression in response to E 2 in most studies (reviewed in Ref. 24 ). This correlates with a lack of the ␣-subunit of HIF-1 in most cultured cells due to the high, nonphysiological oxygen concentration (ϳ20%) that they are exposed to when cultured in 95% air-5% CO 2 . This high oxygen level accelerates the already high rate of HIF-1␣ degradation. As we showed, restoring HIF-1␣ in endometrial cancer cells by preventing its degradation restored the ability of E 2 to strongly induce VEGF expression. As shown by Brodie and co-workers, E2 also rapidly induces an increase in the expression of VEGF in rat mammary tumors (81) and in baboon mammary gland (82) .
VEGF in the endometrium causes swelling of the stroma with exudated plasma (25, 26, 83), the hallmark of rapid E2 action. Inhibition of VEGF activity with a neutralizing antibody confirmed that VEGF is the factor mediating this effect (20). Plasma also accumulates in the human endometrium during both the midproliferative and midsecretory phases of the menstrual cycle (84 -86), periods of peak E 2 production, and in response to exogenous estrogen (87) . The accumulation correlates with the formation of interendothelial cell gaps (12, 88, 89) , which allow free flow of plasma from the vessel lumen into the stroma. VEGF is the only factor known to induce such changes (30, 90). The opening of gaps allows free passage of plasma proteins, such as albumin (91), plasminogen (92) , and fibrinogen (93) , into the stroma, where they are retained. As shown in Fig. 1 , this can be readily demonstrated using protein-sized fluorescent nanoparticles. Interestingly, in contrast to most tissues that contain a rich network of lymphatic vessels that efficiently collect and carry away exudated fluid and protein, the endometrium is almost completely devoid of lymphatic vessels (94 -98) . This indicates that the retention of exudated proteins is important for endometrial function.
The plasma protein most relevant to cell proliferation is IGF-I, which circulates in a 150-kDa complex with two other proteins: an IGF binding protein (usually IGF binding protein-3) and the acid labile subunit. The concentration of IGF-I in plasma is high, ranging from 140 to 400 ng/ml (99) . The passage of IGF-I from the blood into the stroma of a tissue appears to occur almost entirely via the paracellular route, i.e. through gaps between endothelial cells (64, 65) . It is often overlooked that E2 itself circulates not in free form but bound to sex hormone-binding globulin and albumin, proteins which drastically retard its passage into most tissues (100, 101) . Thus, increased permeability to plasma proteins would also accelerate the transit of E2 from the vascular compartment.
There is direct evidence that inhibition of VEGF significantly retards E 2 -induced epithelial cell mitosis (102, 103) . Smith and co-workers (103) showed that treatment of mice with the soluble VEGF receptor, an inhibitor of VEGF activity, reduced epithelial cell proliferation by half. Similarly, inhibiting VEGF activity in mouse mammary glands severely retards the development and function of the alveolar epithelial compartment (104, 105) .
Incorporating VEGF and Hyperpermeability in a New Model of E2-Induced Cell Proliferation
Based on the evidence that VEGF and the hyperpermeability it induces could play a critical role in E2 action, we propose a new working model of E2-induced epithelial cell proliferation in the endometrium (Fig. 2) . It reconciles many previously conflicting findings, including the con- fusion about the roles of endocrine vs. paracrine factors: E2 of endocrine origin induces the production of VEGF, a paracrine-acting factor, which in turn causes the transit of additional endocrine E2 and IGF-I from the circulation. It also explains why cells in culture show little or no proliferative response to E2 unless serum is present: the addition of serum simply replicates the exudation of plasma in vivo. The sequence of events can be summarized as follows. 1) As the level of circulating E2 rises, enough reaches the uterus to induce the expression of VEGF (an immediate-early response) in endometrial epithelial cells. 2) This initial exposure to E2 may also induce the synthesis and/or activation of cell cycle components in the epithelial cells, initiating their entrance into the cell cycle. 3) VEGF from the epithelial cells acts in a paracrine manner on the rich subepithelial network of blood vessels, inducing the formation of interendothelial cell gaps and the outflow of plasma into the stroma adjacent to the luminal and glandular epithelial cells. The plasma contains additional E2 (protein bound), IGF-I, plasminogen, fibrinogen, and other proteins and smaller molecules that create an environment ideal for cell proliferation. 4) The bolus of E2 and IGF-I drives epithelial cells completely through the cell cycle. In the normal reproductive cycle, the epithelial cells undergo a single wave of proliferation, because 1) E2 declines; 2) the E2-induced expression of VEGF, like that of most immediate-early genes, is transient (19, 21-23); and 3) rising levels of progesterone oppose E2's effects on epithelial cells while stimulating proliferation of stromal cells. This probably also involves VEGF, because its expression is induced by progesterone in stromal cells (19, 73, 74, 76, 78) .
Conclusion
It is hoped that this new hypothesis will prompt more research on E2 action in vivo, especially in the mammary gland and in endometrial and mammary tumors. Unfortunately, there have been almost no studies of the acute effects of E2 on VEGF expression or vascular permeability in the mammary gland, although it was recently shown that epithelial cell proliferation there is highest during proestrus in rats (106) , when E2 levels are highest. E2-induced VEGF expression may also be the critical event in the E2-dependent growth of endometrial and breast tumors. Tumor vessels are often characterized as functionally inferior to normal vessels, in large part because of their "leakiness," but they may actually be well suited to support the function of tumor cells: to proliferate and metastasize. Most studies of VEGF's role in cancer have focused on its ability to induce angiogenesis. Although there have been almost no studies of the acute effects of E2 on VEGF expression in tumors, a recent study did show that VEGF overexpressing MCF-7 cell tumors show enhanced growth and decreased tamoxifen responsiveness in mice (107) . As a downstream mediator of E2 action, any change in a tumor resulting in increased VEGF expression could contribute to E2 independence and resistance to E2 antagonists, as shown in that study.
The involvement of VEGF and hyperpermeability in cell proliferation suggests that targeting VEGF so as to specifically reduce permeability may be a better way to inhibit tumor growth. Furthermore, combination treatments targeting both E2 action or production and VEGFinduced hyperpermeability may also be a more effective treatment for E2-dependent cancers than either alone (108) . Finally, the ability of E2 to enhance permeability suggests ways in which estrogenic compounds might be used to enhance the delivery of drug-coated nanoparticles into E2-dependent tumors (69) .
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FIG. 2.
A new model of E2-induced cell proliferation. An immediateearly effect of E2 in the uterus is the induction of VEGF expression by endometrial luminal epithelial cells (LEC). The VEGF then acts on adjacent stromal microvessels to increase their permeability. This, along with a simultaneous increase in endometrial blood flow, results in the outflow of plasma into the stroma, the edema that is the sine qua non of E2's early effects on the uterus. Plasma is rich in IGF-I and also carries additional E2 bound to serum proteins. This bolus of IGF-I and E2 provides the essential factors required for epithelial cell proliferation. 
